V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

IQVIA Holdings Executive Compensation (FY25)

IQV · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): April 23, 2026
249 figures on this page: 241 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
Ari Bousbib, Chairman and Chief Executive Officer, received $28,128,245 in total compensation for fiscal 2025, and Bousbib's total was 5.2% higher than the $26,732,998 reported for fiscal 2024. For fiscal 2025, the company reported a chief executive pay ratio of 275:1, against median employee compensation of $102,424. The say-on-pay proposal drew 80.1% of votes cast for or against in favor at the meeting held April 23, 2026 for fiscal 2025. The disclosed peer group names AbbVie Inc., Accenture plc, Agilent Technologies, Inc., Amgen Inc. and Avantor, Inc., among others.
Chief executive, fiscal 2025
◇
Ari Bousbib
Latest say-on-pay support
=
April 23, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Ari Bousbib: $26,732,998 → $28,128,245 (5.2% higher)
Say-on-pay support: 82.7% → 80.1% (2.6 points lower)
CEO pay ratio: 343:1 → 275:1 (19.8% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is IQVIA Holdings' chief executive and what were they paid?
Ari Bousbib, Chairman and Chief Executive Officer, received $28,128,245 in total compensation for fiscal 2025. Bousbib's total was 5.2% higher than the $26,732,998 reported for fiscal 2024.
What was IQVIA Holdings' say-on-pay result?
The say-on-pay proposal drew 80.1% of votes cast for or against in favor at the meeting held April 23, 2026 for fiscal 2025.
Which companies are in IQVIA Holdings' peer group?
The disclosed peer group names AbbVie Inc., Accenture plc, Agilent Technologies, Inc., Amgen Inc. and Avantor, Inc., among others.
What is IQVIA Holdings' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 275:1, against median employee compensation of $102,424.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ari Bousbib
Chairman and Chief Executive Officer
◇—◇◇◇◇◇◇
Ronald Bruehlman
Executive Vice President and Chief Financial Officer
◇—◇◇◇◇◇◇
Kevin Young
Executive Vice President, Chief Commercial Officer
◇—◇—◇◇◇◇†
Eric Sherbet
Executive Vice President, General Counsel and Secretary
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ari Bousbib
Chairman and Chief Executive Officer
◇—◇◇◇◇◇◇
Ronald Bruehlman
Executive Vice President and Chief Financial Officer
◇—◇◇◇◇◇◇
Eric Sherbet
Executive Vice President, General Counsel and Secretary
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ari Bousbib
Chairman and Chief Executive Officer
◇—◇◇◇◇◇◇
Ronald Bruehlman
Executive Vice President and Chief Financial Officer
◇—◇◇◇◇◇◇
Eric Sherbet
Executive Vice President, General Counsel and Secretary
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Ari Bousbib
Chairman and Chief Executive Officer
◇—◇◇◇◇◇◇
Ronald Bruehlman
Executive Vice President, Chief Financial Officer
◇—◇◇◇◇◇◇
Alistair Grenfell
President, Commercial Solutions
◇—◇◇◇—◇◇
W. Richard Staub III
President, Research & Development Solutions
◇—◇◇◇—◇◇
Eric Sherbet
Executive Vice President, General Counsel and Secretary
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Alistair R. GrenfellPSU◇◇◇—◇——
Alistair R. Grenfell—◇—————◇
Alistair R. Grenfell—◇——◇——◇
Ari Bousbib—◇——◇——◇
Ari Bousbib—◇——◇——◇
Eric M. Sherbet—◇—————◇
Eric M. Sherbet—◇——◇——◇
Ronald E. Bruehlman—◇——◇——◇
Ronald E. Bruehlman—◇——◇——◇
W. Richard Staub III—◇——◇——◇
W. Richard Staub III—◇——◇——◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Eric SherbetSAR◇—◇1/28/35
PSU◇◇——
PSU◇◇——
SAR◇—◇2/7/34
SAR◇—◇2/13/33
W. StaubSAR◇—◇2/7/34
PSU◇◇——
PSU◇◇——
SAR◇—◇1/28/35
SAR◇—◇2/13/33
PSU◇◇——
Ronald BruehlmanSAR◇—◇2/7/34
PSU◇◇——
PSU◇◇——
SAR◇—◇2/13/33
SAR◇—◇1/28/35
Alistair GrenfellPSU◇◇——
PSU◇◇——
SAR◇—◇2/13/33
SAR◇—◇2/7/34
SAR◇—◇1/28/35
Ari BousbibPSU◇◇——
PSU◇◇——
SAR◇—◇2/13/33
SAR◇—◇2/7/34
SAR◇—◇1/28/35
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John M. Leonard, M.D
Lead independent director
◇◇————◇
James A. Fasano
◇◇————◇
Carol J. Burt
◇◇————◇
Colleen A. Goggins
◇◇————◇
John G. Danhakl
◇◇————◇
Sheila A. Stamps
◇◇————◇
Leslie Wims Morris
◇◇————◇
William G. Kaelin Jr., M.D
◇—————◇
John P. Connaughton
◇—————◇
Ari Bousbib and Todd B. Sisitsky served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee member◇
Compensation committee member◇
Nominating and governance member◇
Equity is delivered as restricted stock units.
Stock ownership guideline: 5x annual cash retainer

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • AbbVie Inc. ABBV
  • Accenture plc ACN
  • Agilent Technologies, Inc. A
  • Amgen Inc. AMGN
  • Avantor, Inc. AVTR
  • Biogen Inc. BIIB
  • Cognizant Technology Solutions Corp. CTSH
  • Danaher Corporation DHR
  • Eli Lilly & Co. LLY
  • Gartner, Inc. IT
  • International Business Machines Corp. IBM
  • Merck & Co., Inc. MRK
  • Pfizer Inc. PFE
  • Pharmaceuticals XFOR
  • Regeneron Pharmaceuticals, Inc. REGN
  • Thermo Fisher Scientific, Inc. TMO
  • Vertex Pharmaceuticals Inc. VRTX
  • Zoetis Inc. ZTS

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025April 23, 2026=◇◇◇
2024April 24, 2025=◇◇◇
2023April 16, 2024=◇◇◇
2022April 18, 2023=◇◇◇
2021April 12, 2022=◇◇◇
2019April 6, 2020=◇◇◇
2016April 6, 2017=◇◇◇
2015September 22, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when IQVIA Holdings files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact IQVIA Holdings disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where IQVIA Holdings sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether IQVIA Holdings' disclosed peer group is defensible, who names IQVIA Holdings back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
249 figures on this page: 241 cited to the filing that reported them, 8 calculated from figures it prints.
241 cited to the filing
8 calculated from the filing

Documents cited

  1. 0001193125-26-173771
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001628280-26-012892
    2025 DIRECTOR COMPENSATION · 2025 Summary Compensation Table · CEO Pay Ratio · Grants of Plan-Based Awards · and 4 more sections
  3. 0001193125-25-093687
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001478242-25-000060
    2024 Summary Compensation Table
  5. 0001193125-24-098516
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001308179-24-000042
    2023 Summary Compensation Table
  7. 0001140361-23-018951
  8. 0001308179-23-000071
    Summary Compensation Table
  9. 0001478242-22-000057
  10. 0001478242-20-000023
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001193125-17-113553
  12. 0001193125-16-717053
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “IQVIA Holdings executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/IQV (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about IQVIA Holdings and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers IQVIA Holdings discloses

The companies named in IQV's own disclosed peer group.

AbbVie Inc.Agilent Technologies, Inc.Amgen Inc.Avantor, Inc.Biogen Inc.Cognizant Technology Solutions Corp.Eli Lilly & Co.International Business Machines Corp.Merck & Co., Inc.Pfizer Inc.Regeneron Pharmaceuticals, Inc.Vertex Pharmaceuticals Inc.Zoetis Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy